Novel agents in the treatment of lung cancerLYNCH, Thomas J; JÄNNE, Pasi A; GURUBHAGAVATULA, Sarada et al.Clinical cancer research. 2004, Vol 10, Num 12, issn 1078-0432, 92 p., 2Conference Proceedings

Cetuximab in advanced non-small cell lung cancerGOVINDAN, Ramaswamy.Clinical cancer research. 2004, Vol 10, Num 12, pp 4241s-4244s, issn 1078-0432, 2Conference Paper

The role of gefitinib in lung cancer treatmentGIACCONE, Giuseppe.Clinical cancer research. 2004, Vol 10, Num 12, pp 4233s-4237s, issn 1078-0432, 2Conference Paper

Novel agents in the treatment of lung cancer: proceedings of the fourth Cambridge ConferenceLYNCH, Thomas J; GURUBHAGAVATULA, Sarada; JACKMAN, David et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 79 p., 2Conference Proceedings

Cyclooxygenase as a target in lung cancerBROWN, Joanne R; DUBOIS, Raymond N.Clinical cancer research. 2004, Vol 10, Num 12, pp 4266s-4269s, issn 1078-0432, 2Conference Paper

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridolSHAPIRO, Geoffrey I.Clinical cancer research. 2004, Vol 10, Num 12, pp 4270s-4275s, issn 1078-0432, 2Conference Paper

Clinical trial design issues in the era of targeted therapiesSCHILLER, Joan H.Clinical cancer research. 2004, Vol 10, Num 12, pp 4281s-4282s, issn 1078-0432, 2Conference Paper

Cytotoxic chemotherapy in advanced Non-Small Cell Lung cancer: A review of standard treatment paradigmsSOCINSKI, Mark A.Clinical cancer research. 2004, Vol 10, Num 12, pp 4210s-4214s, issn 1078-0432, 2Conference Paper

Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignanciesROWINSKY, Eric K.Clinical cancer research. 2004, Vol 10, Num 12, pp 4220s-4226s, issn 1078-0432, 2Conference Paper

Oblimersen sodium (genasense bcl-2 antisense oligonucleotide): A rational therapeutic to enhance apoptosis in therapy of lung cancerHERBST, Roy S; FRANKEL, Stanley R.Clinical cancer research. 2004, Vol 10, Num 12, pp 4245s-4248s, issn 1078-0432, 2Conference Paper

The potential role of proteasome inhibitors in the treatment of lung cancerBUNN, Paul A.Clinical cancer research. 2004, Vol 10, Num 12, pp 4263s-4265s, issn 1078-0432, 2Conference Paper

The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancerPEREZ-SOLER, Roman.Clinical cancer research. 2004, Vol 10, Num 12, pp 4238s-4240s, issn 1078-0432, 2Conference Paper

Molecularly targeted approaches to the chemoprevention of lung cancerKHURI, Fadlo R; COHEN, Victor.Clinical cancer research. 2004, Vol 10, Num 12, pp 4249s-4253s, issn 1078-0432, 2Conference Paper

Farnesyl transferase inhibitors for patients with lung cancerJOHNSON, Bruce E; HEYMACH, John V.Clinical cancer research. 2004, Vol 10, Num 12, pp 4254s-4257s, issn 1078-0432, 2Conference Paper

Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agentADJEI, Alex A.Clinical cancer research. 2004, Vol 10, Num 12, pp 4276s-4280s, issn 1078-0432, 2Conference Paper

International conference: Early Stage Lung Cancer: New Approaches to Evaluation and Treatment, Cambridge, MA, USA, October 1-2, 2004LYNCH, Thomas J; GURUBHAGAVATULA, Sarada; HEYMACH, John V et al.Clinical cancer research. 2005, Vol 11, Num 13, issn 1078-0432, 90 p., 2Conference Proceedings

L-BLP25 : A peptide vaccine strategy in non-small cell lung cancer. DiscussionSANGHA, Randeep; BUTTS, Charles; LYNCH, Thomas et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4652s, 2Conference Paper

Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancerSANDLER, Alan B; JOHNSON, David H; HERBST, Roy S et al.Clinical cancer research. 2004, Vol 10, Num 12, pp 4258s-4262s, issn 1078-0432, 2Conference Paper

The biology of epidermal growth factor receptor in lung cancerSCAGLIOTTI, Giorgio V; SELVAGGI, Giovanni; NOVELLO, Silvia et al.Clinical cancer research. 2004, Vol 10, Num 12, pp 4227s-4232s, issn 1078-0432, 2Conference Paper

Antibodies to the epidermal growth factor receptor in non-small cell lung cancer : Current status of matuzumab and panitumumab. DiscussionSOCINSKI, Mark A; SANDIER, Alan; LYNCH, Thomas et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4597s-4601s, 2Conference Paper

The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer. DiscussionENGELMAN, Jeffrey A; PEREZ-SOLER, Roman; LYNCH, Thomas et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4637s-4640s, 2Conference Paper

Bevacizumab in non-small cell lung cancer. DiscussionSANDLER, Alan; LYNCH, Thomas; HERBST, Roy et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4613s-4616s, 2Conference Paper

Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patientsSUK, Rebecca; GURUBHAGAVATULA, Sarada; PARK, Sohee et al.Clinical cancer research. 2005, Vol 11, Num 4, pp 1534-1538, issn 1078-0432, 5 p.Article

Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapyWEI ZHOU; GURUBHAGAVATULA, Sarada; LIU, Geoffrey et al.Clinical cancer research. 2004, Vol 10, Num 15, pp 4939-4943, issn 1078-0432, 5 p.Article

Erlotinib : Recent clinical results and ongoing studies in non-small cell lung cancer. DiscussionPEREZ-SOLER, Roman; LYNCH, Thomas; MARTINS, Renato et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4689s-4592s, 2Conference Paper